3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
4
Active not recruiting
2
Withdrawn
1
Terminated
1
Sponsor Class
OTHER
2
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Conditions
Muscle Invasive Bladder Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
185
Carboplatin
133
Paclitaxel
102
Cisplatin
102
Gemcitabine
86
Pemetrexed
80
durvalumab
75
Nivolumab
66
Docetaxel
56
atezolizumab
52
Bevacizumab
50
Cyclophosphamide
49
Dexamethasone
45
Capecitabine
45
Oxaliplatin
43
130-nm albumin-bound paclitaxel
42
Rituximab
40
Fulvestrant
39
Lenalidomide
38
Fluorouracil
38
Prednisone
32
osimertinib
31
olaparib
29
Leucovorin
29
venetoclax
28
fludarabine
28
Trastuzumab
27
Doxorubicin
27
Etoposide
25
Cetuximab
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
INDUSTRY
×
vistusertib
×
Clear all
NCT02546661
2025-12-29
BISCAY
AstraZeneca
Phase 1
Active not recruiting
117 enrolled
NCT03334617
2025-10-27
HUDSON
AstraZeneca
Phase 2
Active not recruiting
528 enrolled
16 charts